CD26/DPPIV cleaves CXCL10 to regulate its biological activity, and DPPIV inhibition prevents degradation of CXCL10, thus increasing CXCR3+ T lymphocyte levels and reducing tumor growth [20]. This evidence concerns the gene DPP4 and neoplasm.